NO20015887L - Pyrazinontrombinantagonister - Google Patents

Pyrazinontrombinantagonister

Info

Publication number
NO20015887L
NO20015887L NO20015887A NO20015887A NO20015887L NO 20015887 L NO20015887 L NO 20015887L NO 20015887 A NO20015887 A NO 20015887A NO 20015887 A NO20015887 A NO 20015887A NO 20015887 L NO20015887 L NO 20015887L
Authority
NO
Norway
Prior art keywords
alkyl
pyrazinontrombinantagonister
fuhvc
sulfinylalkyl
sulfonylalkyl
Prior art date
Application number
NO20015887A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015887D0 (no
Inventor
Christopher S Burgey
Kyle A Robinson
Peter D Williams
Craig A Coburn
Terry A Lyle
Philip E Sanderson
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20015887D0 publication Critical patent/NO20015887D0/no
Publication of NO20015887L publication Critical patent/NO20015887L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20015887A 1999-06-04 2001-12-03 Pyrazinontrombinantagonister NO20015887L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13753899P 1999-06-04 1999-06-04
US14429199P 1999-07-16 1999-07-16
PCT/US2000/015140 WO2000075134A1 (en) 1999-06-04 2000-06-01 Pyrazinone thrombin inhibitors

Publications (2)

Publication Number Publication Date
NO20015887D0 NO20015887D0 (no) 2001-12-03
NO20015887L true NO20015887L (no) 2002-01-23

Family

ID=26835338

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015887A NO20015887L (no) 1999-06-04 2001-12-03 Pyrazinontrombinantagonister

Country Status (31)

Country Link
US (1) US6455532B1 (de)
EP (1) EP1189899B1 (de)
JP (2) JP4495377B2 (de)
KR (1) KR20020029653A (de)
CN (1) CN1353705A (de)
AT (1) ATE232527T1 (de)
AU (1) AU761982B2 (de)
BG (1) BG106263A (de)
BR (1) BR0011260A (de)
CA (1) CA2373999C (de)
CZ (1) CZ20014343A3 (de)
DE (1) DE60001414T2 (de)
DK (1) DK1189899T3 (de)
DZ (1) DZ3264A1 (de)
EA (1) EA004372B1 (de)
EE (1) EE200100641A (de)
ES (1) ES2190417T3 (de)
HK (1) HK1047277A1 (de)
HR (1) HRP20010903A2 (de)
HU (1) HUP0202366A3 (de)
IL (1) IL146393A0 (de)
IS (1) IS6158A (de)
MX (1) MXPA01012505A (de)
NO (1) NO20015887L (de)
NZ (1) NZ515454A (de)
PL (1) PL352558A1 (de)
SK (1) SK17532001A3 (de)
TR (1) TR200103491T2 (de)
UA (1) UA58636C2 (de)
WO (1) WO2000075134A1 (de)
YU (1) YU84301A (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265094A1 (en) 2000-06-01 2001-12-11 Merck And Co., Inc. Pyrazinone thrombin inhibitors
FR2818277B1 (fr) * 2000-12-14 2003-01-24 Servier Lab Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6528503B2 (en) 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
WO2002050056A1 (en) 2000-12-18 2002-06-27 Merck & Co., Inc. Benzylamine derivatives and their use as thrombin inhibitors
US7144899B2 (en) 2001-02-09 2006-12-05 Merck & Co., Inc. Thrombin inhibitors
US7262211B2 (en) 2001-12-04 2007-08-28 Dendreon Corporation Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
FR2867780B1 (fr) * 2004-03-19 2006-05-19 Servier Lab Nouveaux derives de 4-oxo-4,6,7,8-tetrahydropyrrolo (1,2-a) pyrazine-6-carboxamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
WO2011056806A1 (en) * 2009-11-03 2011-05-12 Diakron Pharmaceuticals, Inc. Process for the preparation of pyrazinone thrombin inhibitor and its intermediates
CA2857953A1 (en) 2011-11-07 2013-05-16 Diakron Pharmaceuticals Inc. An extended release formulation of a direct thrombin inhibitor
CN115677511B (zh) * 2022-10-26 2024-06-21 南通华祥医药科技有限公司 一种2,2-二氟丙胺盐酸盐的合成方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795486A (en) 1986-09-26 1989-01-03 Boehner Beat Aminopyrazinones and aminotriazinones
TW201303B (de) 1990-07-05 1993-03-01 Hoffmann La Roche
GB9207145D0 (en) 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
CN1038586C (zh) 1991-05-01 1998-06-03 大制药株式会社 吡嗪衍生物的制备方法
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW223629B (de) 1992-03-06 1994-05-11 Hoffmann La Roche
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
AU670381B2 (en) 1993-04-30 1996-07-11 Merck & Co., Inc. Thrombin inhibitors
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
EP0820453A4 (de) 1995-04-04 2001-08-29 Merck & Co Inc Thrombin-inhibitoren
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
WO1997001338A1 (en) * 1995-06-27 1997-01-16 Merck & Co., Inc. Pyridinone-thrombin inhibitors
PL329441A1 (en) * 1996-04-23 1999-03-29 Merck & Co Inc Pyrasinone-type thrombin inhibitors
US5668289A (en) 1996-06-24 1997-09-16 Merck & Co., Inc. Pyridinone thrombin inhibitors
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
JP2001508796A (ja) * 1997-01-22 2001-07-03 メルク エンド カンパニー インコーポレーテッド トロンビン阻害薬
CA2283704A1 (en) * 1997-03-24 1998-10-01 Merck & Co., Inc. Thrombin inhibitors
US5866573A (en) 1997-04-21 1999-02-02 Merck & Co., Inc. Pyrazinone thrombin inhibitors
EP1017393A4 (de) 1997-09-05 2002-01-23 Merck & Co Inc Pyrazinon thrombininhibitoren
AU753479B2 (en) * 1998-05-19 2002-10-17 Merck & Co., Inc. Pyrazinone thrombin inhibitors
PL352368A1 (en) 1999-05-19 2003-08-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade

Also Published As

Publication number Publication date
EE200100641A (et) 2003-02-17
US6455532B1 (en) 2002-09-24
NO20015887D0 (no) 2001-12-03
JP4495377B2 (ja) 2010-07-07
TR200103491T2 (tr) 2002-12-23
EA200200005A1 (ru) 2002-06-27
EP1189899A1 (de) 2002-03-27
UA58636C2 (uk) 2003-08-15
BR0011260A (pt) 2002-03-19
PL352558A1 (en) 2003-08-25
EA004372B1 (ru) 2004-04-29
ES2190417T3 (es) 2003-08-01
DK1189899T3 (da) 2003-03-10
BG106263A (en) 2002-06-28
HUP0202366A2 (en) 2002-10-28
CA2373999C (en) 2007-01-02
CN1353705A (zh) 2002-06-12
DZ3264A1 (fr) 2000-12-14
YU84301A (sh) 2004-07-15
HRP20010903A2 (en) 2003-04-30
SK17532001A3 (sk) 2002-05-09
CA2373999A1 (en) 2000-12-14
KR20020029653A (ko) 2002-04-19
NZ515454A (en) 2004-02-27
IL146393A0 (en) 2002-07-25
HUP0202366A3 (en) 2005-07-28
HK1047277A1 (zh) 2003-02-14
AU5457100A (en) 2000-12-28
MXPA01012505A (es) 2002-07-02
ATE232527T1 (de) 2003-02-15
DE60001414D1 (en) 2003-03-20
CZ20014343A3 (cs) 2002-03-13
DE60001414T2 (de) 2003-11-06
IS6158A (is) 2001-11-13
JP2010150275A (ja) 2010-07-08
EP1189899B1 (de) 2003-02-12
WO2000075134A1 (en) 2000-12-14
AU761982B2 (en) 2003-06-12
JP2003501426A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
NO20015887L (no) Pyrazinontrombinantagonister
NO20031471L (no) Glykoformer av faktor VII
AU2002316459A1 (en) Methods of treating cytokine mediated diseases
WO2002101007A3 (en) Antipathogenic benzamide compounds
WO1998057937A3 (en) Inhibitors of factor xa with a neutral p1 specificity group
DE60219402D1 (de) Verhinderung des Gesprächabbruchs wenn der Zellradius verkleinert wird
BR9909242A (pt) Inibidores de fosfolipase a2
AU2001274220A1 (en) Serine protease inhibitors
WO2001094480A3 (en) Reduction of surface tension
AU3110999A (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
BR0111451A (pt) Inibidores de serina protease
ATE355284T1 (de) Inhibitoren von serinproteasen
GB0114185D0 (en) Compounds
AU2001266575A1 (en) Chemical compounds
LU92263I2 (fr) Imépitoïne et ses dérivés pharmaceutiquement acceptables (PEXION)
EP0726072A3 (de) Zusammenstellung zur Behandlung von Hypertonie und congestiven Herzensagens, die ein Angiotensin-II-Antagonist und ein Endopeptidase Inhibitor enthält
IL141830A0 (en) Chemiluminescent 1,2-dioxetane
BR9816029A (pt) Composições detergente
DK1204659T3 (da) Serotonerge benzofuraner
DE50101861D1 (de) Tocotrienolchinon- zyklisierungsprodukte mit antihypercholesterin wirkung
ATE263826T1 (de) Verwendung von polyoxypropylenierten/polyoxyethylenierten terpenderivaten als entfettungsmittel von harten oberflächen
EP1476149A4 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2
NO20021248D0 (no) Fremgangsmåte for å stabilisere hvitheten av ligninholdige fibröse materialer, stabilisert sammensetning og fibrösematerialer som er stabilisert med denne
AU2001218083A1 (en) Ace inhibitor-vasopressin antagonist combinations
DK1066041T3 (da) Anvendelse af 17-alpha-estradiol derivater til terapi af bivirkninger under og/eller efter en GnRHa-terapi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application